trending Market Intelligence /marketintelligence/en/news-insights/trending/lb8tWCMUdK9X-2WKRwOnGA2 content esgSubNav
In This List

Mitsubishi Tanabe completes acquisition of NeuroDerm

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Mitsubishi Tanabe completes acquisition of NeuroDerm

Mitsubishi Tanabe Pharma Corp. completed the $1.12 billion acquisition of Israel-based pharmaceutical company NeuroDerm Ltd.

Under the deal, a unit of Mitsubishi Tanabe was merged with and into NeuroDerm, with the latter being the surviving corporation and a wholly owned subsidiary of the Japanese pharmaceutical company.

NeuroDerm's shareholders were entitled to receive $39 in cash per share. NeuroDerm's ordinary shares will cease to trade on the Nasdaq global market.